Grade

09:00 - 09:15
1) Increased use of hypodracionated RT in Elderly patients with GBM in USA from 2004 - 2015

FELIPE COELHO

Palestrante

09:00 - 09:15
2) Isoeffective hypofractionation for elderly or frail patients with GBM

FELIPE COELHO

Palestrante

09:15 - 09:30
1) Change in hippocampal volume as a function of Radiation dose - Results from a Prospective Trial with Standardized Imaging and Morprometric Evalution

BRUNA BONACCORSI

BELO HORIZONTE / MG Palestrante

09:15 - 09:30
2) Development and internal validation of a predictive suores for vertebral compression fratura after stereotactic body radiation therapy for sinal metastases

BRUNA BONACCORSI

BELO HORIZONTE / MG Palestrante

09:30 - 09:45
1) PriCoTTF trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

RAMON GATTO

SALVADOR / BA Palestrante

09:30 - 09:45
2) Potencial Benefits of Ultra-High Dose Rate Radiation (FLASH) for treatment of Brain Tumors

RAMON GATTO

SALVADOR / BA Palestrante

09:45 - 10:00
1) Radiation Therapy for Diffuse Glioma

KARINE CAMPAGNOLO

Palestrante

09:45 - 10:00
2) Dosimetric and Volumetric of failure analisys of a phase II clinical trial of 18F-DOPA-PET directed dose escalated radiotherapy for glioblastoma

KARINE CAMPAGNOLO

Palestrante

10:00 - 10:10
Discussão ao vivo

KARINE CAMPAGNOLO

Palestrante

RAMON GATTO

SALVADOR / BA Palestrante

BRUNA BONACCORSI

BELO HORIZONTE / MG Palestrante

FELIPE COELHO

Palestrante

10:10 - 10:25
NIMG-62 - 68(GA)DOTATATE PET-based radiation contouring creates smaller and more precise radiation volumes for meningioma patients

DANIELLE GUJANWSKI

Palestrante

10:10 - 10:25
Investigational PET Tracers in Patients with Brain Metastases

DANIELLE GUJANWSKI

Palestrante

10:25 - 10:40
Value and Limitations of Advanced MRI for Brain Tumor Imaging

DAVID ARAUJO

UBERLANDIA / MG Palestrante

10:40 - 10:50
Discussão ao vivo

DANIELLE GUJANWSKI

Palestrante

DAVID ARAUJO

UBERLANDIA / MG Palestrante

10:50 - 11:00
Craniopharyngiomas and Meningiomas (Sat 20, 7:20)

DANIELLE FERREIRA NEVES

RIO DE JANEIRO / RJ Palestrante

10:50 - 11:00
CTIM-30 - Phase II trial of pembrolizumab in recurrent and residual high-grade meningiomas

DANIELLE FERREIRA NEVES

RIO DE JANEIRO / RJ Palestrante

11:00 - 11:05
CTIM-31 - A Phase II, open-label, single arm trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma and Hemangiopericytoma

MIRELA SOUTO

Palestrante

11:00 - 11:05
CTNI-54 - A single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib provided for sporadic patients with grade II-III meningiomas that recur or progress after surgery and radiation

MIRELA SOUTO

Palestrante

11:05 - 11:20
Keynote Presentation: CAR T Cell Therapy for Glioblastoma: Promise and Challenges

FABIANA VIOLA

Palestrante

11:20 - 11:30
CTIM-25 - A randomized phase 3 study of nivolumab or placebo combined with radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma with methylated MGMT promoter: CheckMate 548

CAMILA MARTINS FONSECA GALIZZI

Palestrante

11:20 - 11:30
CTIM-13 - Phase 1 Clinical Trial of Oncolytic Viral Immunotherapy with CAN-2409 + Valacyclovir in Combination with Nivolumab and Standard of Care (SOC) in Newly Diagnosed High-Grade Glioma (HGG)

CAMILA MARTINS FONSECA GALIZZI

Palestrante

11:30 - 11:35
LTBK-05 - Clinical Efficacy of ONC201 in Recurrent H3 K27M-Mutant Diffuse Midline Glioma Patients

DANIELA BARROS GALVÃO

Palestrante

11:35 - 12:05
Final Session: Keynote Presentation: The 2021 WHO Classification of CNS Tumors.

LEONARD MEDEIROS DA SILVA

SAO PAULO / SP Palestrante

12:05 - 12:20
Discussão ao vivo

LEONARD MEDEIROS DA SILVA

SAO PAULO / SP Palestrante

DANIELA BARROS GALVÃO

Palestrante

CAMILA MARTINS FONSECA GALIZZI

Palestrante

FABIANA VIOLA

Palestrante

MIRELA SOUTO

Palestrante

DANIELLE FERREIRA NEVES

RIO DE JANEIRO / RJ Palestrante